Comprehensive Genomic Alterations in Common Cancer Cell Lines Revealed by Exome Sequencing

Author(s):  
Han Chang ◽  
Donald G. Jackson ◽  
Paul S. Kayne ◽  
Petra B. Ross-Macdonald ◽  
Rolf-Peter Ryseck ◽  
...  
PLoS ONE ◽  
2011 ◽  
Vol 6 (6) ◽  
pp. e21097 ◽  
Author(s):  
Han Chang ◽  
Donald G. Jackson ◽  
Paul S. Kayne ◽  
Petra B. Ross-Macdonald ◽  
Rolf-Peter Ryseck ◽  
...  

2018 ◽  
Vol 33 (1) ◽  
pp. e4692 ◽  
Author(s):  
Ambarish Mondal ◽  
Rajat K. Tripathy ◽  
Parul Dutta ◽  
Manas Kumar Santra ◽  
Anvarhusein A. Isab ◽  
...  

2019 ◽  
Author(s):  
Neetha Nanoth Vellichirammal ◽  
Abrar Albahrani ◽  
Jasjit K. Banwait ◽  
You Li ◽  
Babu Guda

2019 ◽  
Author(s):  
Neetha Nanoth Vellichirammal ◽  
Abrar Albahrani ◽  
Jasjit K. Banwait ◽  
You Li ◽  
Babu Guda

2008 ◽  
Vol 267 (1) ◽  
pp. 49-54 ◽  
Author(s):  
Xueying Mao ◽  
Bryan D. Young ◽  
Tracy Chaplin ◽  
Janet Shipley ◽  
Yong-Jie Lu

2019 ◽  
Author(s):  
Kanika Arora ◽  
Minita Shah ◽  
Molly Johnson ◽  
Rashesh Sanghvi ◽  
Jennifer Shelton ◽  
...  

AbstractTo test the performance of a new sequencing platform, develop an updated somatic calling pipeline and establish a reference for future benchmarking experiments, we sequenced 3 common cancer cell lines along with their matched normal cell lines to great sequencing depths (up to 278X coverage) on both Illumina HiSeqX and NovaSeq sequencing instruments. Somatic calling was generally consistent between the two platforms despite minor differences at the read level. We designed and implemented a novel pipeline for the analysis of tumor-normal samples, using multiple variant callers. We show that coupled with a high-confidence filtering strategy, it improves the accuracy of somatic calls. We also demonstrate the utility of the dataset by creating an artificial purity ladder to evaluate the somatic pipeline and benchmark methods for estimating purity and ploidy from tumor-normal pairs. The data and results of the pipeline are made accessible to the cancer genomics community.


2021 ◽  
Author(s):  
Niantao Deng ◽  
Andre Minoche ◽  
Kate Harvey ◽  
Andrei Goga ◽  
Alex Swarbrick

Abstract BackgroundBreast cancer cell lines (BCCLs) and patient-derived xenografts (PDX) are the most frequently used models in breast cancer research. Despite their widespread usage, genome sequencing of these models is incomplete, with previous studies only focusing on targeted gene panels, whole exome or shallow whole genome sequencing. Deep whole genome sequencing is the most sensitive and accurate method to detect single nucleotide variants and indels, gene copy number and structural events such as gene fusions. ResultsHere we describe deep whole genome sequencing (WGS) of commonly used BCCL and PDX models using the Illumina X10 platform with an average ~ 60x coverage. We identify novel genomic alterations, including point mutations and genomic rearrangements at base-pair resolution, compared to previously available sequencing data. Through integrative analysis with publicly available functional screening data, we annotate new genomic features likely to be of biological significance. CSMD1 , previously identified as a tumor suppressor gene in various cancer types, including head and neck, lung and breast cancers, has been identified with deletion in 50% of our PDX models, suggesting an important role in aggressive breast cancers. ConclusionsOur WGS data provides a comprehensive genome sequencing resource of these models.


2015 ◽  
Author(s):  
Mirna Jarosz ◽  
Michael Schnall-Levin ◽  
Grace X. Y. Zheng ◽  
Patrick Marks ◽  
Sofia Kyriazopoulou-Panagiotopoulou ◽  
...  

2019 ◽  
Vol 18 (8) ◽  
pp. 1460-1471 ◽  
Author(s):  
Sunetra Das ◽  
Rupa Idate ◽  
Kathryn E. Cronise ◽  
Daniel L. Gustafson ◽  
Dawn L. Duval

Sign in / Sign up

Export Citation Format

Share Document